Roughly 162,000 people worldwide are estimated to be living with cystic fibrosis across 94 countries, though about a third of them may not yet be diagnosed.1PubMed. Worldwide rates of diagnosis and effective treatment for cystic fibrosis That number, however, hides enormous variation depending on where you look and whom you count. CF has long been described as the most common life-shortening genetic disease in people of European descent, but the global picture is more complicated and more interesting than that framing suggests.
The Global Numbers
A 2022 modeling study estimated that about 162,400 people live with CF in the 94 countries analyzed. Of those, roughly 105,000 (about 65 percent) have been diagnosed, leaving an estimated 57,000 people with undiagnosed CF.2PubMed. Worldwide rates of diagnosis and effective treatment for cystic fibrosis The undiagnosed fraction is heavily concentrated in low- and middle-income countries where newborn screening programs are limited and access to sweat testing or genetic testing can be difficult. In much of sub-Saharan Africa, South Asia, and Southeast Asia, registries simply don’t exist, so the true number of people with CF could be higher than the models suggest.3PubMed Central. Expanding Cystic Fibrosis Registries to the Rest of the World
Europe has the highest documented prevalence by region. The frequency there has driven extensive newborn screening programs, and many countries have had CF registries for decades. A 10-year screening program in Brittany, France, for instance, found an incidence of about 1 in 2,900 births.4The Lancet. Neonatal screening for cystic fibrosis: 10 years’ experience in Brittany (France) By contrast, data from East Asia suggest rates as low as 1 in 100,000 to 1 in 350,000, while West Asian populations report rates somewhere between 1 in 4,000 and 1 in 10,000.5Biomedical and Biotechnology Research Journal. Geographical Distribution of Cystic Fibrosis; The past 70 Years of Data Analyzis Those East Asian figures almost certainly undercount cases, given the lack of centralized registries and routine screening in most of the region.
Why Prevalence Varies So Much by Geography and Ancestry
CF is caused by mutations in a single gene, but more than 2,000 different mutations have been catalogued. The specific mutations circulating in a population, how common they are, and how likely two carriers are to meet and have children together all determine that population’s CF rate. In Northern Europe, one mutation (known as F508del) dominates, accounting for nearly 90 percent of CF chromosomes in Denmark but only about 26 percent in Algeria.6Human Mutation. Geographic distribution and regional origin of 272 cystic fibrosis mutations in European populations Southern European populations have a more diverse set of mutations, and that diversity grows further as you move into the Middle East, South Asia, and East Asia.7European Journal of Human Genetics. Spatial patterns of cystic fibrosis mutation spectra in European populations
The mutation spectrum matters practically, not just genetically. Even within a small geographic area, the mix of mutations can differ. Northern Ireland’s mutation profile, for example, differs from that of neighboring Ireland and Great Britain despite their proximity.8PubMed Central. Mutation characterisation of the cystic fibrosis transmembrane conductance regulator (CFTR) gene in people with cystic fibrosis in Northern Ireland These local differences affect everything from which screening panels work well in a given population to which targeted therapies will be effective.
In the Middle East and North Africa, consanguinity (marriage between close relatives) increases the chance that both parents carry the same recessive mutation. Multiple studies of Arab countries have noted that CF is frequently reported in populations where consanguineous marriage is common.9PubMed. Spectrum of mutations of cystic fibrosis in the 22 Arab countries: A systematic review A study of a Middle Eastern population found that between 5.5 and 7 percent of newborns were carriers of a pathogenic or likely pathogenic variant, a rate comparable to carrier frequencies found in European populations.10PubMed. CFTR mutational screening by next-generation sequencing reveals novel variants and a high carrier rate in a Middle Eastern population The disease itself, though, remains underdiagnosed in the region because systematic screening is rare.11Clinical Epidemiology and Global Health. A systematic review of the epidemiology of cystic fibrosis in arab countries: An update
The Underdiagnosis Problem
The perception that CF is overwhelmingly a disease of white Europeans has created a self-reinforcing gap. Screening panels used in clinical genetic testing were historically designed around the mutations most common in European-descent populations. A study in Genetics in Medicine found that both the clinical definition of CF and the mutation panels sold commercially are biased toward detecting risk in people of European descent, with South and East Asian populations being severely underrepresented.12Genetics in Medicine. Targeted mutation screening panels expose systematic population bias in detection of cystic fibrosis risk If the standard panel doesn’t include the mutations common in a given region, affected individuals slip through the net.
In Asia, CF has been described as under-reported rather than truly rare. Clinical studies from the region document a severe disease course, but the mutation spectrum is heterogeneous, and the most common European mutation (F508del) is found at much lower rates.13PubMed. Epidemiology and genetics of cystic fibrosis in Asia: In preparation for the next-generation treatments A recent review of CF cases across Southeast Asia found only 50 documented cases from five countries combined, with a mutation spectrum distinct from that seen in Western populations.14PubMed Central. Cystic fibrosis in Vietnam and Southeast Asia: underdiagnosis and genetic spectrum Whether the true prevalence in East and Southeast Asia is genuinely 50 to 100 times lower than in Europe or whether the gap is substantially narrowed once underdiagnosis is accounted for remains an open question.
Among Black populations, CF carrier frequency may be higher than the older textbook estimates. A study of South African Black individuals found a carrier frequency of about 1 in 91 for a single mutation. When corrected for that mutation’s variable share of all CF-causing alleles in the population, the overall carrier frequency was estimated somewhere between 1 in 14 and 1 in 59, which would predict CF at rates between 1 in 784 and 1 in roughly 14,000 births.15Journal of Medical Genetics. Cystic fibrosis carrier frequencies in populations of African origin That upper-bound estimate would put the rate in the same range as some European populations. People from racial and ethnic minority backgrounds who do develop CF tend to have worse clinical outcomes, likely a combination of diagnostic delay, different mutation profiles, and disparities in access to care.16PubMed Central. Racial inequities and rare CFTR variants: Impact on cystic fibrosis diagnosis and treatment
CF in Latin America
Latin America illustrates the gap between the disease’s true burden and how well it’s tracked. The region’s mixed European, Indigenous, and African ancestry means CF is present at meaningful rates, and researchers have argued for decades that the disease is “not rare” there, though reliable population-level data remain scarce.17PubMed. Epidemiology of cystic fibrosis in Latin America: preliminary communication A newborn screening program in southeastern Mexico over five years found a birth prevalence of about 1 in 13,700, lower than European averages but still substantial.18PubMed. Newborn cystic fibrosis screening in southeastern Mexico: Birth prevalence and novel CFTR gene variants The most common mutation in that region was F508del, but novel variants turned up as well, suggesting the mutation pool in Latin America isn’t just a diluted version of the European one.
Access to CF registries, neonatal screening, specialized clinics, and newer treatments varies dramatically across the region. Brazil has established a national registry, but many countries still lack one. The interplay between diverse genetic backgrounds, limited screening infrastructure, and variable healthcare access means Latin America’s CF burden is still being pieced together.19PubMed. Cystic fibrosis in Latin America-Improving the awareness
Atypical CF and the Diagnostic Gray Zone
Not everyone with CF-causing mutations develops the classic disease. Atypical CF accounts for roughly 2 percent of diagnosed cases and involves milder symptoms, sometimes limited to a single organ system, with sweat chloride levels that can be normal or borderline.20PubMed. Atypical cystic fibrosis and CFTR-related diseases These individuals can go undiagnosed well into adulthood, sometimes being identified only when they develop male infertility, chronic sinusitis, or unexplained pancreatitis. Because their symptoms fluctuate and don’t match the textbook picture, atypical CF is easy to miss.21PubMed Central. Atypical cystic fibrosis: identification in the primary care setting
The existence of this milder spectrum complicates prevalence counts. Many population estimates are based on newborn screening or clinical diagnosis, both of which tend to catch the classic, severe form. People with atypical presentations are harder to count, and some may never receive a CF diagnosis at all. That makes it likely that the true prevalence of CFTR-related disease, broadly defined, is higher than the commonly cited figures.
Birth Prevalence Is Declining in Some Regions
In countries with widespread carrier screening, the birth rate of CF has been falling. In parts of northern Italy, where carrier testing has been widely available since the 1990s, a study published in JAMA found a steady annual decline in CF birth incidence. The drop was concentrated in the eastern region where more carrier couples were identified, showing a clear correlation between the volume of screening and the number of CF births.22JAMA. Association Between Carrier Screening and Incidence of Cystic Fibrosis Updated analysis of the same region showed that birth prevalence in the eastern area fell from about 1 in 2,700 in 1993 to approximately 1 in 14,200 by 2013.23Genetics in Medicine. Cystic fibrosis carrier screening effects on birth prevalence and newborn screening
A similar trend has been documented in Canada, where estimated CF birth rates followed a linear decline from the late 1980s onward, reaching about 1 in 3,600 by the year 2000.24PubMed. Cystic fibrosis birth rates in Canada: a decreasing trend since the onset of genetic testing The mechanism is straightforward: when prospective parents learn they’re both carriers, some choose prenatal testing and, depending on results, may terminate affected pregnancies or pursue other reproductive options. In populations where carrier screening hasn’t been broadly adopted, these declines have not occurred.
The Growing Adult Population
Even as fewer babies are born with CF in screened populations, the total number of people living with CF is growing in most high-income countries. The reason is improved survival. Adults now outnumber children in the CF population in most developed countries.25PubMed. Ageing in cystic fibrosis and long-term survival In the United States, median survival age rose from 29 years in 1990 to about 39 years in 2012. After approval of the triple-combination CFTR modulator therapy in 2019, survival gains accelerated dramatically, and median survival reached 68 years by 2023.26PubMed Central. Impact of CFTR Modulators on Longitudinal Cystic Fibrosis Survival and Mortality: Review and Secondary Analysis
These therapies target the underlying protein defect rather than just managing symptoms, and they have reshaped the clinical trajectory for the majority of patients whose mutations are eligible. The evidence for their effect on life expectancy is still accumulating, since the drugs haven’t been available long enough for mortality studies in the traditional sense, and indirect evidence from lung function, nutritional status, and hospitalization rates is used as a proxy.27PubMed Central. CFTR modulator therapies – Effect on life expectancy in people with cystic fibrosis Still, the trajectory is unmistakable. In the UK, a forecasting model projected a 28 percent increase in the number of CF adults between 2017 and 2030, with more than a third of that adult population expected to be over 40.28PubMed Central. The changing demography of the cystic fibrosis population: forecasting future numbers of adults in the UK European projections from an earlier model had predicted the number of CF adults in several countries would increase by roughly 78 percent between 2010 and 2025.29European Respiratory Journal. Projections of cystic fibrosis patient numbers in Europe up to 2025
The upshot is a demographic inversion. A disease that was once almost exclusively pediatric is becoming increasingly an adult one, which brings new clinical challenges: CF-related diabetes, liver disease, bone loss, cancer screening, fertility planning, and the psychological weight of managing a chronic condition over decades.
Socioeconomic Disparities Within Countries
Prevalence figures tell you how many people have CF; survival data tell you how long they live. Both are shaped by wealth. In England and Wales, analysis of death certificates over five decades showed that people with CF from lower socioeconomic backgrounds died younger. The lowest socioeconomic group, along with individuals classified as long-term unemployed or permanently sick, fared worst. One interpretation is that wealthier families were faster to access newly available specialist treatment centers, or that better-educated parents were quicker to adopt emerging treatments once they were published in the medical literature.30BMJ. Association between socioeconomic status, sex, and age at death from cystic fibrosis in England and Wales (1959 to 2008): cross sectional study In Canada, the overall demographics at diagnosis are similar between white and non-white patients in terms of sex distribution and age, but broader outcome data show that racial and ethnic minority populations tend to have worse clinical trajectories.31PubMed. Disparities in outcomes by race and ethnicity in the Canadian cystic fibrosis population
The introduction of CFTR modulators risks widening these gaps. Only about 12 percent of all diagnosed CF patients worldwide were estimated to be receiving triple-combination therapy as of the modeling study’s publication.32PubMed. Worldwide rates of diagnosis and effective treatment for cystic fibrosis Access depends on national healthcare funding, insurance coverage, drug approval timelines, and the mutation eligibility criteria. For the 57,000 or so people estimated to have undiagnosed CF, the question of modulator access is moot because they haven’t even gotten a diagnosis yet.
Why Is the Carrier Rate So High in Some Populations?
A question that has puzzled geneticists for decades is why CF carrier rates are as high as they are, particularly in Northern European populations where roughly 1 in 25 people carries a single copy of a CF-causing mutation. Recessive diseases that kill in childhood should, over time, become vanishingly rare as affected individuals die before reproducing. The fact that CF hasn’t been driven to near-zero suggests that carrying one copy of a mutated CFTR gene confers some survival advantage, similar to the way carrying one copy of the sickle cell mutation provides some protection against malaria.
One leading hypothesis involves resistance to infectious diarrheal diseases. The CFTR protein controls chloride and water movement across cell surfaces, including in the gut. A study in an Indonesian population found an association between CFTR genotypes and susceptibility to typhoid fever, with certain CFTR variants appearing to reduce the risk of infection by the typhoid-causing bacterium.33PubMed. Susceptibility to typhoid fever is associated with a polymorphism in the cystic fibrosis transmembrane conductance regulator (CFTR) The idea is that carriers, with one normal and one mutated copy, have slightly altered fluid secretion in the gut that makes it harder for certain intestinal pathogens to gain a foothold. In historical European populations ravaged by cholera, typhoid, and other diarrheal infections, even a modest survival edge could have maintained high carrier rates over centuries. The hypothesis remains debated, and the true answer may involve more than one selective pressure, but it helps explain why CF persists at frequencies that seem paradoxically high for a lethal disease.
What the Registry Gaps Mean for Global Numbers
The countries where CF epidemiology is best understood, the United States, Canada, much of Western Europe, Australia, and New Zealand, represent only a fraction of the world’s population. CF registries exist in these places because the disease was recognized early and healthcare systems invested in tracking it. For most of Africa, South and Southeast Asia, Central Asia, and parts of Latin America, there are no national registries.34PubMed Central. Expanding Cystic Fibrosis Registries to the Rest of the World That means any global prevalence number is a model, not a census. The 162,000-person estimate extrapolates from known carrier frequencies, observed birth rates, and assumed survival curves, each of which introduces uncertainty.
Expanding registry coverage is more than just an academic exercise. Registries are what allow researchers to identify which mutations are circulating in a population, which in turn determines whether new modulator therapies will work there. Without that infrastructure, patients in unregistered countries are effectively locked out of the therapeutic advances reshaping CF care in the West. Even basic data like average age at diagnosis and survival curves remain unknown for hundreds of millions of people living in countries where CF has been reported in case series but never systematically counted.